Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Elanco to become No. 2 in animal health with $7.6 billion Bayer deal

Elanco Animal Health agreed to buy Bayer’s veterinary drugs unit in a cash and stock deal valued at $7.6 billion, creating the second-largest maker of medicines for pets and livestock and expanding Elanco’s reach online.

Read More »

Jazz Pharmaceuticals Announces Acquisition of Cavion

Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.

Read More »

Bayer buys BlueRock in $600 million bet on stem cell therapies

German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.

Read More »

Siemens Healthineers to Acquire Corindus Vascular Robotics

Corindus Vascular Robotics entered into a definitive merger agreement to be acquired by Siemens Healthineers AG for an aggregate purchase price of approximately $1.1 billion.

Read More »

Glaukos and Avedro Announce Definitive Acquisition Agreement

Ophthalmic medical technology and pharmaceutical company Glaukos Corp. will acquire hybrid ophthalmic pharma and medical tech company Avedro Inc. in an all-stock transaction.

Read More »

Permira Snaps Up Cambrex in $2.4 Billion Deal

Shares of Cambrex Corp. were up more than 46 percent in trading after the company announced an agreement to be acquired by an affiliate of the Permira funds for $60 per share, totaling $2.4 billion.

Read More »

Sanofi Reports Strong Second-Quarter 2019

Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.

Read More »

Roche lifts full-year outlook after H1 sales rise 18 percent

Roche lifted the company’s full-year sales outlook after revenue in first-half 2019 rose 18 percent, helped by newer drugs including the MS medicine Ocrevus and the cancer immunotherapy Tecentriq.

Read More »

AbbVie Makes ‘Transformational’ Move with $63 Billion Acquisition of Allergan

Illinois-based AbbVie announced that the company will acquire Ireland-based Allergan for $63 billion in a cash and stock deal.

Read More »

Bristol-Myers plans to divest Celgene’s psoriasis drug

Bristol-Myers Squibb Co. offered to divest Celgene Corp.’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom